Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from JNJ

Johnson & Johnson (NYSE: JNJ) released their financial report for the second quarter of 2022, this week, demonstrating strong growth and promising guidance for the rest of the year. Analysts seem to agree, as the consensus rating for JNJ is MODERATE BUY.

Benzinga

Looking At Johnson & Johnson's Recent Whale Trades

Someone with a lot of money to spend has taken a bullish stance on Johnson & Johnson (NYSE:JNJ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

4 Outperforming Stocks for People Who Hate Volatility

The stock market has been experiencing immense volatility lately as investors remain concerned over the multi-decade high inflation and the Fed’s aggressive interest rates to control it. However, fundamentally sound stocks Johnson & Johnson (JNJ), Coca-Cola FEMSA (KOF), KT Corporation (KT), and Weis Markets (WMK) are outperforming the broader market.…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Here's Why Every Investor Might Want to Buy Shares of JNJ

Including dividends, Johnson & Johnson (JNJ) has delivered exceptional returns over the past decade. Given the company’s robust financials, strong dividend-paying history, solid growth prospects, and higher-than-industry profitability, the stock could be an excellent investment amid the current uncertain market conditions. Read on….

StockNews.com

Looking At Johnson & Johnson's Recent Whale Trades

Benzinga

Check Out What Whales Are Doing With JNJ

A whale with a lot of money to spend has taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 15 strange trades.

Benzinga

Here's How Much You Would Have Made Owning Johnson & Johnson Stock In The Last 15 Years

Johnson & Johnson (NYSE:JNJ) has outperformed the market over the past 15 years by 1.01% on an annualized basis producing an average annual return of 7.22%. Currently, Johnson & Johnson has a market capitalization of $465.27 billion.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

2 Low-Beta Mega Stocks That Could Outperform the Market

The stock market has witnessed a free fall since the beginning of the year due to the Fed’s interest rate hikes and the recession fears. Moreover, interest rates are expected to rise further this year. Given the heightened volatility in the market, we think low beta mega stocks Johnson &…

StockNews.com

What Are Whales Doing With Johnson & Johnson

A whale with a lot of money to spend has taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 12 strange trades.

Benzinga

Worried About A Market Meltdown? Then Buy These Stable Stocks Now

The rising inflation and the Fed’s aggressive rate hikes to clamp down on inflation are making investors anxious. Moreover, with analysts expecting multiple interest rate hikes in the coming months, recessionary fears are growing. As the market experiences a bout of volatility, fundamentally solid stocks Johnson & Johnson (JNJ), Roche…

StockNews.com

Here's How Much You Would Have Made Owning Johnson & Johnson Stock In The Last 15 Years

Johnson & Johnson (NYSE:JNJ) has outperformed the market over the past 15 years by 1.05% on an annualized basis producing an average annual return of 7.34%. Currently, Johnson & Johnson has a market capitalization of $469.49 billion.

Benzinga

Check Out What Whales Are Doing With JNJ

A whale with a lot of money to spend has taken a noticeably bullish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 20 strange trades.

Benzinga

3 Dividend-Paying Healthcare Stocks to Outperform in the Bear Market

The bear market is creating a challenging environment for investors. One place to find outperformance could be high0-quality, healthcare stocks that are paying a dividend. Therefore, investors should consider dividend-paying healthcare stocks like Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), and Unitedhealth Group (UNH). .

StockNews.com

5 Dividend Aristocrats To Buy Now

Last week, the Fed raised its benchmark interest rates three-quarters of a percentage point, marking the most aggressive hike since 1994. And with analysts predicting the economy to slip into a recession, we think dividend aristocrats Abbott (ABT), AbbVie (ABBV), Genuine Parts (GPC), Johnson & Johnson (JNJ), and Sysco (SYY)…

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Looking At Johnson & Johnson's Recent Whale Trades

Someone with a lot of money to spend has taken a bearish stance on Johnson & Johnson (NYSE:JNJ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

StockNews.com

5 Durable Stocks to Strengthen Your Portfolio

Given the current market turmoil caused due to surging inflation and the Fed’s aggressive interest rate hikes to bring prices down, it could be wise to invest in stocks that do not fluctuate significantly in adverse market conditions. The solid stability of Johnson & Johnson (JNJ), Coca-Cola FEMSA (KOF), Marubeni…

Benzinga

What Are Whales Doing With Johnson & Johnson

Benzinga

Johnson & Johnson-AbbVie Partnered Lymphoma Drug Slows Disease Progression, Data Shows

Johnson & Johnson (NYSE:JNJ) and AbbVie Inc (NYSE:ABBV) announced primary results from the Phase 3 SHINE study of Imbruvica (ibrutinib) plus bendamustine-rituximab (BR) and rituximab maintenance in older patients with newly diagnosed mantle cell lymphoma (MCL). The combination regime significantly reduced the risk of disease progression or death by 25% compared to placebo plus BR…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Check Out What Whales Are Doing With JNJ

Benzinga

Check Out What Whales Are Doing With JNJ

A whale with a lot of money to spend has taken a noticeably bullish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 12 strange trades.

StockNews.com

3 Stocks to Buy if You Think a Recession is Imminent

Wall Street is becoming increasingly concerned about a recession. And with sky-high inflation, the Fed no longer is an ally for investors. For investors who believe that a recession is likely, here are 3 stocks to consider buying: Johnson & Johnson (JNJ), EZCORP (EZPW), and Dollar Tree (DLTR). .

StockNews.com

5 All-Weather Stocks to Protect Your Portfolio from a Bear Market

In the current, uncertain market environment, one of the best strategies to protect one’s portfolio is to invest in stocks capable of withstanding all market and economic conditions. With fears of a looming recession, we think investors could look to add the stocks of all-weather companies Constellation Brands (STZ), Johnson…

Benzinga

US Raises Objection To Johnson & Johnson's High Cost Lawyer For Talc Bankruptcy Case: Reuters

Johnson & Johnson (NYSE: JNJ) is ready to cough up an hourly rate of $2,465 in a bid to add Hogan Lovells partner Neal Katyal to its legal team for the talc liability case.

Benzinga

What Are Whales Doing With Johnson & Johnson

Benzinga

What Is Happening With Endo Shares Today

Endo International Plc (NASDAQ:ENDP) initiated negotiations with its lenders and senior bondholders regarding a possible reorganization of more than $8 billion of its debt, the Wall Street Journal reported, citing people familiar with the matter. Lenders began talks after the company reported disappointing earnings early this month for 1Q 2022, driven by the loss…

1 … 11 12 13 14

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.